Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Cue Biopharma Second Quarter 2024 Earnings Call. All participants will be in a listen-only mode.
Cue Biopharma Inc. (CUE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Slate Path Capital David Greenspan | 2,402,455 | $1,819,139 | 0.02% | |
| 2. | Millennium Management Israel Englander | 358,974 | $271,815 | -28% | 0% |
| 3. | Point72 Asia (Singapore) Steve Cohen | 24,098 | $18,247 | -55% | 0% |
| 4. | 14,400 | $10,904 | +13% | 0% | |
| 5. | 2,600 | $1,969 | -77% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.76 | 4,000 | Officer | 135,638 | 2023-08-25 | Filing | |
| $2.86 | 3,000 | Officer, Director | 134,578 | 2023-08-14 | Filing | |
| $3.75 | 28,000 | Director | 28,000 | 2022-05-27 | Filing | |
| $3.34 | 55,000 | Director | 940,000 | 2022-05-24 | Filing | |
| $3.52 | 150,000 | Director | 885,000 | 2022-05-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.28 | 9,325 | Director | 357 | 2023-03-23 | Filing | |
| $18.02 | 1,361 | Director | 0 | 2021-11-16 | Filing | |
| $17.92 | 18,815 | Director | 0 | 2021-11-15 | Filing | |
| $18.05 | 8,000 | Officer | 94,038 | 2021-11-15 | Filing | |
| $15.07 | 20,000 | Officer | 94,038 | 2021-11-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,338,765 | $6,174,340 | 0% | |
| 2. | 2,132,905 | $5,630,869 | 0% | |
| 3. | 1,755,028 | $4,633,274 | 1.02% | |
| 4. | 813,285 | $2,147,353 | 0% | |
| 5. | 683,695 | $1,804,955 | 0% |
News See All
Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.
Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the presentation.
Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to the Cue Biopharma Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded.
Hedge Fund and Insider Trading News: George Soros, Alan Howard, Ken Griffin, Bill Ackman, Elliott Management, Bridgewater Associates, Angelo Gordon & Co., Averill Partners, Cue Biopharma Inc (CUE), Noble Corporation (NE), and More
The world's largest hedge fund is sounding the alarm over a possible return to 1970s-style "stagflation," as the Federal Reserve moves to tame sky-high inflation.
5 Pharmaceutical Stocks to Buy According to Lawrence Hawkins' Prosight Capital
In this article, we discuss 5 pharmaceutical stocks to buy according to Lawrence Hawkins' Prosight Capital.
Is CUE A Good Stock To Buy Now?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Keep Buying Cue Biopharma, Inc. (CUE)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.